sch 16134 has been researched along with Sleep Initiation and Maintenance Disorders in 39 studies
quazepam: structure given in first source
Sleep Initiation and Maintenance Disorders: Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Within a double-blind, comparative study on the effects of the long-half-life benzodiazepine (BDZ), quazepam, and the short-half-life BDZ, triazolam, on clinical symptomatology, sleep and anxiety of 45 patients with insomnia based on a mild to moderate generalized anxiety disorder (GAD) (ICD-9 code: 307." | 9.07 | Insomnia in generalized anxiety disorder: polysomnographic, psychometric and clinical investigations before, during and after therapy with a long- versus a short-half-life benzodiazepine (quazepam versus triazolam). ( Anderer, P; Brandstätter, N; Frey, R; Grünberger, J; Klösch, G; Mandl, M; Saletu, B; Wetter, T; Zeitlhofer, J, 1994) |
| "Within a double-blind, comparative study on the effects of the long-half-life benzodiazepine (BDZ), quazepam, and the short-half-life BDZ, triazolam, on clinical symptomatology, sleep and anxiety of 45 patients with insomnia based on a mild to moderate generalized anxiety disorder (GAD) (ICD-9 code: 307." | 5.07 | Insomnia in generalized anxiety disorder: polysomnographic, psychometric and clinical investigations before, during and after therapy with a long- versus a short-half-life benzodiazepine (quazepam versus triazolam). ( Anderer, P; Brandstätter, N; Frey, R; Grünberger, J; Klösch, G; Mandl, M; Saletu, B; Wetter, T; Zeitlhofer, J, 1994) |
| "The mean number of insomnia complaints was significantly (p < ." | 2.67 | Evaluation of the safety and efficacy of quazepam for the treatment of insomnia in psychiatric outpatients. ( Mendels, J, 1994) |
| "Rebound insomnia, a worsening of sleep difficulty beyond baseline levels, can complicate the physician's attempt to use regularly scheduled drug holidays in the management of insomniac patients." | 2.67 | Feasibility of an every-other-night regimen in insomniac patients: subjective hypnotic effectiveness of quazepam, triazolam, and placebo. ( Scharf, MB, 1993) |
| "Temazepam did not produce any behavioral side effects during either drug condition." | 2.66 | Quazepam and temazepam: effects of short- and intermediate-term use and withdrawal. ( Bixler, EO; Jacoby, JA; Kales, A; Kales, JD; Soldatos, CR; Vela-Bueno, A, 1986) |
| " In contrast, triazolam dosing did not significantly improve any of the major sleep efficiency parameters, and there was a rapid development of tolerance for the drug's slight initial effectiveness." | 2.66 | Comparison of short and long half-life benzodiazepine hypnotics: triazolam and quazepam. ( Bixler, EO; Kales, A; Manfredi, RL; Niklaus, DE; Soldatos, CR; Vela-Bueno, A, 1986) |
| " The resuls confirm that quazepam in a dosage of 15 mg/night is safe and that it is more effective than placebo in treating insomnia in older patients." | 2.65 | Short-term treatment with quazepam of insomnia in geriatric patients. ( Martinez, HT; Serna, CT, 1982) |
| "In a short-term clinical study, 60 insomniac outpatients were randomly assigned to receive either 30 mg of quazepam or placebo orally for five consecutive nights." | 2.65 | Evaluation of short-term treatment with 30 mg of quazepam in insomniac outpatients. ( O'Hair, DE; Winsauer, HJ, 1981) |
| " Yet, these agents can produce adverse effects such as tolerance to the hypnotic effect, rebound insomnia, next-day residual drowsiness, as well as amnesia and complex behaviours such as sleep-walking, sleep-eating and sleep-driving." | 2.61 | Reintroduction of quazepam: an update on comparative hypnotic and adverse effects. ( Moniri, NH, 2019) |
| "Quazepam and flurazepam share pharmacokinetic properties that result in prevention of early-morning insomnia, daytime rebound anxiety, and withdrawal rebound insomnia." | 2.38 | Quazepam and flurazepam: differential pharmacokinetic and pharmacodynamic characteristics. ( Battista, D; Hilbert, JM, 1991) |
| " The only notable side effect seen with quazepam is a variable degree of daytime sedation, which can be minimized by intermittent use of the 15 mg dose when necessary and use of the 7." | 2.38 | Quazepam: hypnotic efficacy and side effects. ( Kales, A, 1990) |
| " Further definition of certain characteristics of its profile--such as its long term use and potential for development of tolerance or dependence, effects on psychomotor skills, efficacy of the 7." | 2.37 | Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia. ( Ankier, SI; Goa, KL, 1988) |
| "Early morning insomnia, a significant increase in wakefulness during the final hours of drug nights, occurred after 1 or 2 weeks of nightly administration of benzodiazepine hypnotics with short elimination half-lives, when tolerance had begun to develop." | 1.27 | Early morning insomnia with rapidly eliminated benzodiazepines. ( Bixler, EO; Kales, A; Kales, JD; Soldatos, CR, 1983) |
| " Some loss of effectiveness was noted during long-term use of both doses of quazepam and, to a lesser extent, of flurazepam." | 1.26 | Quazepam and flurazepam: long-term use and extended withdrawal. ( Bixler, EO; Jacoby, J; Kales, A; Kales, JD; Soldatos, CR; Vela-Bueno, A, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (58.97) | 18.7374 |
| 1990's | 14 (35.90) | 18.2507 |
| 2000's | 1 (2.56) | 29.6817 |
| 2010's | 1 (2.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moniri, NH | 1 |
| Nishiyama, T | 1 |
| Yamashita, K | 1 |
| Yokoyama, T | 1 |
| Imoto, A | 1 |
| Manabe, M | 1 |
| Kales, A | 10 |
| Scharf, MB | 3 |
| Soldatos, CR | 9 |
| Bixler, EO | 8 |
| Bianchi, SB | 1 |
| Schweitzer, PK | 2 |
| Jacoby, JA | 3 |
| Uhthoff, HK | 1 |
| Brunet, JA | 1 |
| Aggerwal, A | 1 |
| Varin, R | 1 |
| Tietz, EI | 1 |
| Roth, T | 2 |
| Zorick, FJ | 1 |
| Piccione, P | 1 |
| Kramer, M | 1 |
| Dement, W | 1 |
| Seidel, W | 1 |
| Carskadon, M | 1 |
| Caldwell, JR | 1 |
| Martinez, HT | 1 |
| Serna, CT | 1 |
| Kales, JD | 5 |
| Mendels, J | 4 |
| Stern, S | 1 |
| Hernández Lara, R | 1 |
| Del Rosal, PL | 1 |
| Ponce, MC | 1 |
| Aden, GC | 1 |
| Thatcher, C | 1 |
| O'Hair, DE | 1 |
| Winsauer, HJ | 1 |
| Vela-Bueno, A | 4 |
| Jacoby, J | 1 |
| Landy, DA | 1 |
| Saletu, B | 2 |
| Anderer, P | 1 |
| Brandstätter, N | 1 |
| Frey, R | 1 |
| Grünberger, J | 2 |
| Klösch, G | 1 |
| Mandl, M | 1 |
| Wetter, T | 1 |
| Zeitlhofer, J | 1 |
| Roth, TG | 1 |
| Roehrs, TA | 2 |
| Koshorek, GL | 1 |
| Greenblatt, DJ | 2 |
| Rosenthal, LD | 1 |
| Walsh, JK | 1 |
| Mahowald, MW | 1 |
| Hilbert, JM | 1 |
| Battista, D | 1 |
| Dement, WC | 1 |
| Blake, GJ | 1 |
| Ankier, SI | 1 |
| Goa, KL | 1 |
| Bonacci, C | 1 |
| Cucca, S | 1 |
| Martechini, A | 1 |
| Franchino, L | 1 |
| Crolle, G | 1 |
| Niklaus, DE | 1 |
| Manfredi, RL | 1 |
| Mamelak, M | 1 |
| Csima, A | 1 |
| Price, V | 1 |
| Sieghart, W | 1 |
8 reviews available for sch 16134 and Sleep Initiation and Maintenance Disorders
| Article | Year |
|---|---|
Reintroduction of quazepam: an update on comparative hypnotic and adverse effects.
Topics: Benzodiazepines; Drug-Related Side Effects and Adverse Reactions; Humans; Hypnotics and Sedatives; S | 2019 |
Quazepam and flurazepam: differential pharmacokinetic and pharmacodynamic characteristics.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Cricetinae; Flurazepam; Humans; Hy | 1991 |
A review of the safety profiles of benzodiazepine hypnotics.
Topics: Aged; Anti-Anxiety Agents; Benzodiazepines; Central Nervous System; Flurazepam; Half-Life; Humans; H | 1991 |
Criteria for selection of appropriate benzodiazepine hypnotic therapy.
Topics: Anti-Anxiety Agents; Benzodiazepines; Decision Making; Half-Life; Humans; Hypnotics and Sedatives; S | 1991 |
Quazepam: hypnotic efficacy and side effects.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Chemical Phenomena; Chemistry; Hal | 1990 |
Rebound insomnia and elimination half-life: assessment of individual subject response.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Dose-Response Relationship, D | 1985 |
Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia.
Topics: Anti-Anxiety Agents; Benzodiazepines; Humans; Sleep Initiation and Maintenance Disorders | 1988 |
Behavioral side effects of benzodiazepine hypnotics.
Topics: Amnesia; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Flurazepam; Humans; Hypnotics and Sedatives; | 1985 |
21 trials available for sch 16134 and Sleep Initiation and Maintenance Disorders
| Article | Year |
|---|---|
Effects of quazepam as a preoperative night hypnotic: comparison with brotizolam.
Topics: Adult; Aged; Azepines; Benzodiazepines; Dose-Response Relationship, Drug; Dreams; Female; Humans; Hy | 2007 |
Quazepam, a new benzodiazepine hypnotic: intermediate-term sleep laboratory evaluation.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Electroencephalography; Elect | 1980 |
A clinical study of quazepam in hospitalized patients with insomnia.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Double-Blin | 1981 |
The acute effect of quazepam on the sleep of chronic insomniacs. A dose-response study.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Chronic Disease; Clinical Trials as Topic; | 1981 |
Short-term quazepam treatment of insomnia in geriatric patients.
Topics: Aged; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Double-Blind Method; Humans; M | 1982 |
Short-term treatment with quazepam of insomnia in geriatric patients.
Topics: Aged; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Double-Blind Method; Female; H | 1982 |
Evaluation of the short-term treatment of insomnia in out-patients with 15 milligrams of quazepam.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Double-Blind Method; Female; | 1983 |
Short-term study of quazepam 15 milligrams in the treatment of insomnia.
Topics: Adult; Aged; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Double-Blind Method; Fe | 1983 |
Quazepam in the short-term treatment of insomnia in outpatients.
Topics: Adult; Ambulatory Care; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Double-Blind | 1983 |
Evaluation of short-term treatment with 30 mg of quazepam in insomniac outpatients.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Double-Blind Method; Female; | 1981 |
Evaluation of the safety and efficacy of quazepam for the treatment of insomnia in psychiatric outpatients.
Topics: Adolescent; Adult; Ambulatory Care; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety Disorders; Be | 1994 |
Insomnia in generalized anxiety disorder: polysomnographic, psychometric and clinical investigations before, during and after therapy with a long- versus a short-half-life benzodiazepine (quazepam versus triazolam).
Topics: Adult; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Double-Blind Method; Female; Humans; Hypnotics | 1994 |
Feasibility of an every-other-night regimen in insomniac patients: subjective hypnotic effectiveness of quazepam, triazolam, and placebo.
Topics: Anti-Anxiety Agents; Benzodiazepines; Circadian Rhythm; Double-Blind Method; Drug Administration Sch | 1993 |
Hypnotic effects of low doses of quazepam in older insomniacs.
Topics: Aged; Anti-Anxiety Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; Hypnot | 1997 |
Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the Multiple Sleep Latency Test.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Anxiety Agents; Benzodiazepines; Circa | 1991 |
Quazepam: a new hypnotic.
Topics: Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Humans; Sleep Initiation and Mainten | 1990 |
Rebound insomnia and elimination half-life: assessment of individual subject response.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Dose-Response Relationship, D | 1985 |
Quazepam and temazepam: effects of short- and intermediate-term use and withdrawal.
Topics: Adult; Aged; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Drug Evaluation; Half-L | 1986 |
Comparison of short and long half-life benzodiazepine hypnotics: triazolam and quazepam.
Topics: Adult; Aged; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Double-Blind Method; Dr | 1986 |
Nocturnal traffic noise, sleep, and quality of awakening: neurophysiologic, psychometric, and receptor activity changes after quazepam.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Double-Blind Method; Female; | 1985 |
The role of low-dose benzodiazepines in the management of insomnia.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Female; Humans; Male; Middle | 1985 |
11 other studies available for sch 16134 and Sleep Initiation and Maintenance Disorders
| Article | Year |
|---|---|
Dose-response studies of quazepam.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; | 1981 |
Daytime alertness, insomnia, and benzodiazepines.
Topics: Adult; Anti-Anxiety Agents; Arousal; Benzodiazepines; Double-Blind Method; Flurazepam; Humans; Loraz | 1982 |
Early morning insomnia with rapidly eliminated benzodiazepines.
Topics: Anti-Anxiety Agents; Benzodiazepines; Flurazepam; Half-Life; Humans; Midazolam; Sleep; Sleep Initiat | 1983 |
Quazepam and flurazepam: long-term use and extended withdrawal.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Drug Evaluation; Flurazepam; Half-Life; Humans; Middle | 1982 |
Article questioned.
Topics: Anti-Anxiety Agents; Benzodiazepines; Humans; Peer Review; Periodicals as Topic; Placebos; Research | 1994 |
Avoiding the blanket approach to insomnia. Targeted therapy for specific causes.
Topics: Anti-Anxiety Agents; Benzodiazepines; Chronic Disease; Diagnosis, Differential; Estazolam; Flurazepa | 1991 |
Introduction: pharmacokinetic considerations. Benzodiazepine hypnotics: the interface of basic and clinical science.
Topics: Anti-Anxiety Agents; Benzodiazepines; Drug Utilization; Humans; Hypnotics and Sedatives; Sleep Initi | 1991 |
Quazepam for insomnia.
Topics: Anti-Anxiety Agents; Benzodiazepines; Humans; Hypnotics and Sedatives; Sleep Initiation and Maintena | 1991 |
[Clinical considerations on the efficacy and tolerability of a new sleep-inducing benzodiazepine for elderly patients: quazepam].
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Benzodiazepines; Drug Evaluation; Drug Tolerance; Fema | 1987 |
Quazepam: sleep laboratory studies of effectiveness and withdrawal.
Topics: Anti-Anxiety Agents; Benzodiazepines; Flurazepam; Humans; Sleep Initiation and Maintenance Disorders | 1985 |
Effects of quazepam and triazolam on the sleep of chronic insomniacs: a comparative 25-night sleep laboratory study.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Chronic Disease; Drug Tolerance; Female; Humans; Male; | 1985 |